Merrimack Initiates Phase 1 Clinical Study of MM-398 in Combination With Cyclophosphamide for Pediatric Solid Tumors
January 23, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398...
Merrimack to Present Preclinical Data at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium
January 13, 2014 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that preclinical data on an analysis of HER2, HER3 and heregulin levels in gastric and...
Merrimack to Present at the 32nd Annual J.P. Morgan Healthcare Conference
December 20, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the 32nd Annual...
Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer
December 13, 2013 08:30 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced Phase 1 clinical trial results for MM-302, a novel HER2-targeted liposomal doxorubicin...
Merrimack Pharmaceuticals to Present Phase 1 Data on MM-302 in Patients With Advanced HER2-Positive Breast Cancer
December 06, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 6, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 data evaluating safety of the novel agent MM-302 in patients with advanced...
Merrimack to Present at the Oppenheimer 24th Annual Healthcare Conference
December 04, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Oppenheimer...
Merrimack and Actavis Announce Nanotechnology Collaboration
November 26, 2013 07:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass. and DUBLIN, Ireland, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to...
Merrimack Pharmaceuticals' MM-121 Demonstrates Positive Signal in Two Phase 2 ER/PR+ Breast Cancer Studies
November 26, 2013 07:00 ET
|
Merrimack Pharmaceuticals
Metastatic Breast Cancer Study Reinforces Biomarker Findings From Previously Reported MM-121 Study in Ovarian Cancer
Neoadjuvant Breast Cancer Study Shows Favorable Comparison in pCR Rate...
Merrimack Provides Third Quarter 2013 Operating Update and Financial Results
November 07, 2013 07:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
Merrimack Pharmaceuticals Updates Timing of Third Quarter 2013 Investor Conference Call
November 05, 2013 16:41 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2013 Investor Conference call at 8 a.m....